Voyager Therapeutics Reports 2024 Financial Results and Progress

Voyager Therapeutics Inc. ( (VYGR) ) has released its Q4 earnings. Here is a breakdown of the information Voyager Therapeutics Inc. presented to its investors.

Voyager Therapeutics, Inc. is a biotechnology company focused on using genetic approaches to treat neurological diseases, with a pipeline that includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, and ALS. In its latest earnings report, Voyager highlighted significant progress in its tau-targeting programs, including the VY1706 gene therapy and VY7523 antibody, both aimed at Alzheimer’s disease. The company reported a decrease in collaboration revenue, leading to a net loss for the year, but maintained a strong cash position expected to support operations into mid-2027. Key financial metrics showed a decline in collaboration revenue from $250 million in 2023 to $80 million in 2024, while research and development expenses increased due to pipeline advancements. Looking ahead, Voyager anticipates several milestones, including data presentations and regulatory filings, which could drive future growth and development in its therapeutic programs.